Assembly Biosciences (ASMB) Fundamental Analysis: Revenue, Earnings & Valuation

7.99 / 10

Outperform

Fundamental analysis rates ASMB as Outperform with an 8.0/10 score. Key strengths include a low current‑liabilities‑to‑total‑liabilities ratio (95.95%), robust interest coverage (35.11%), strong inventory turnover (103.9), and favorable PB‑ROE, Revenue‑MV and Asset‑MV metrics, indicating solid financial health.

Analysis Checks(10/10)

Revenue-MV

Value-0.06

Score3/3

Weight26.17%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value153.52

Score2/3

Weight0.36%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-2.98%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value95.95

Score2/3

Weight1.01%

1M Return0.36%

PB-ROE

Value-0.07

Score3/3

Weight32.96%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.01

Score3/3

Weight2.29%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.03%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value153.52

Score2/3

Weight0.15%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-2.87%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight45.95%

1M Return11.61%

Is ASMB fundamentally strong?

ASMB scores 7.99/10 on fundamentals and holds a Discounted valuation at present. Backed by its -5.10% ROE, -8.47% net margin, -76.36 P/E ratio, 2.26 P/B ratio, and 91.78% earnings growth, these metrics solidify its Outperform investment rating.